Significance of CXCL10 as a Biomarker of Liver Cirrhosis

Siqi LI; Wenlin TAI

doi:10.12259/j.issn.2095-610X.S20220711

Volume 43 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(7): 55-61

Siqi LI, Wenlin TAI. Significance of CXCL10 as a Biomarker of Liver Cirrhosis[J]. Journal of Kunming Medical University, 2022, 43(7): 55-61. doi: 10.12259/j.issn.2095-610X.S20220711

Citation:

Siqi LI, Wenlin TAI. Significance of CXCL10 as a Biomarker of Liver Cirrhosis[J]. Journal of Kunming Medical University, 2022, 43(7): 55-61. doi: 10.12259/j.issn.2095-610X.S20220711

Siqi LI, Wenlin TAI. Significance of CXCL10 as a Biomarker of Liver Cirrhosis[J]. Journal of Kunming Medical University, 2022, 43(7): 55-61. doi: 10.12259/j.issn.2095-610X.S20220711

Citation:

Siqi LI, Wenlin TAI. Significance of CXCL10 as a Biomarker of Liver Cirrhosis[J]. Journal of Kunming Medical University, 2022, 43(7): 55-61. doi: 10.12259/j.issn.2095-610X.S20220711

PDF( 921 KB)

Significance of CXCL10 as a Biomarker of Liver Cirrhosis

doi: 10.12259/j.issn.2095-610X.S20220711

Siqi LI,
Wenlin TAI^,

Dept. of Clinical Laboratory，The 2nd Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650101，China

Received Date: 2022-04-08
Available Online: 2022-07-01
Publish Date: 2022-07-14

Abstract

Abstract

Objective To investigate the potential of CXCL10 as a noninvasive biomarker of liver cirrhosis and its mechanism in the progression of liver fibrosis. Methods Peripheral blood samples of EDTA-K2 anticoagulant tubes were collected from cirrhotic patients （n = 64） and healthy subjects （n = 64） in the Second Affiliated Hospital of Kunming Medical University from March to August 2021, and the basic information and laboratory examination results of the patients were strictly recorded. CXCL10 concentration in plasma was determined by ELISA. The relationship between CXCL10 expression level and biochemical test results was analyzed. ROC curve was used to analyze the predictive value of plasma CXCL10 levels for cirrhosis. Results The plasma CXCL10 concentration in patients with cirrhosis was significantly higher than that in healthy subjects, and the difference was statistically significant （P < 0.0001）. Plasma CXCL10 levels were positively correlated with ALT, AST, PT, APTT and DD in patients with cirrhosis （P < 0.05）. The area under ROC curve of CXCL10 is 0.8264, which has good diagnostic performance. Conclusion CXCL10 can be used as a non-invasive biomarker and a potential therapeutic target for liver cirrhosis.
- Liver fibrosis,
- CXCL10,
- Liver cirrhosis

FullText(HTML)

References(19)

References

[1]	Zoubek M E,Trautwein C,Strnad P. Reversal of liver fibrosis:From fiction to reality[J]. Best Pract Res Clin Gastroenterol,2017,203(3):12-41.
[2]	Moon A M,Singal A G,Elliot B. Contemporary epidemiology of chronic liver disease and cirrhosis - science direct[J]. Clinical Gastroenterology and Hepatology,2020,18(12):50-66.
[3]	Simon T G,Roelstraete B,Hartjes K,et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality[J]. Journal of Hepatology,2021,20(5):135-141.
[4]	Campos-Murgu í a A,Román-Calleja B,Toledo-Coronado I V,et al. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19[J]. Digestive and Liver Disease,2021,48(21):48-56.
[5]	Caviglia J M,Yan J,Jang M K,et al. MicroRNA-21 and dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis[J]. Hepatology,2017,67(Suppl.1):65-72.
[6]	Lee Y S,Kim S Y,Ko E,et al. Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells[J]. Scientific Reports,2017,7(1):30-45.
[7]	Holt A P,Haughton E L,Lalor P F,et al. Liver myofibroblasts regulate Infiltration and positioning of lymphocytes inhuman liver[J]. Gastroenterology,2009,136(2):5-14. doi: 10.1053/j.gastro.2008.09.006
[8]	Barrow F,Khan S,Fredrickson G,et al. Microbiota‐Driven Activation of intrahepatic B Cells aggravates nonalcoholic steatohepatitis through innate and adaptive signaling[J]. Hepatology,2018,74(23):84-96.
[9]	Lafoz E,Ruart M,Anton A,et al. The endothelium as a driver of liver fibrosis and regeneration[J]. Cells,2020,9(4):29-35.
[10]	Barrow F,Khan S,Fredrickson G,et al. Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2:a role for exosomes in metabolic switch of liver nonparenchymal cells[J]. The FASEB Journal,2019,33(7):41-56.
[11]	Motonobu,Watanabe,Soichiro,et al. Platelets contribute to the reduction of liver fibrosis in mice[J]. Journal of Gastroenterology & Hepatology,2009,21(17):23-32.
[12]	Ding B S,Ca O Z,Lis R,et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis[J]. Nature,2014,505(7481):97-102. doi: 10.1038/nature12681
[13]	Tannapfel A,Dienes H P,Lohse A W. The indications for liver biopsy[J]. Deutsches Ä rzteblatt International,2012,109(27-28):477-483.
[14]	Song Z Y,Ke-Bang W U,Li-Li W U,et al. Research progress on rapid serological assays for diagnosis of Japanese Encephalitis B[J]. China Animal Husbandry & Veterinary Medicine,2015,45(23):69-75.
[15]	Wang R,Ding Q,Yaqoob U,Assuncao T D,et al. Non-invasive assessment of hepatic steatosis:Prospective comparison of the accuracy of imaging examinations[J]. Journal of Hepatology,2010,52(4):79-85.
[16]	Kim S U,Seo Y S,Cheong J Y,et al. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B[J]. Alimentary Pharmacology & Therapeutics,2010,32(3):498-505.
[17]	Wang W J, Xiao P, Xu H Q, et al. Growing burden of alcoholic liver disease in China: A review [J]. 世界胃肠病学杂志: 英文版, 2019, 25（12）: 12. Wang W J,Xiao P,Xu H Q,et al. Growing burden of alcoholic liver disease in China:A review[J]. World Journal Gastroenterology,2019,25(12):12.
[18]	Ahmed Z,Ahmed U,Walayat S,et al. Liver function tests in identifying patients with liver disease[J]. Clinical and Experimental Gastroenterology,2018,11(6):1-7.
[19]	Liu Z,Zhang Z,Huang M,et al. Taurocholic acid is an active promoting factor,not just a biomarker of progression of liver cirrhosis:evidence from a human metabolomic study and in vitro experiments[J]. Bmc Gastroenterology,2018,18(1):112-116. doi: 10.1186/s12876-018-0842-7

Relative Articles(20)

Relative Articles

[1]	Lu ZHANG, Ye LI, Qingqing WANG, Shenghao LI. Advances in Research on the Effects of Liver Cirrhosis on Cardiovascular System and Related Mechanisms. Journal of Kunming Medical University, 2024, 45(6): 1-6. doi: 10.12259/j.issn.2095-610X.S20240601
[2]	Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119
[3]	Peizheng XIANG, Mengli LI, Yan FU. Value of Multiple Scoring Systems in Evaluating the Prognosis of Liver Cirrhosis Complicated with Esophageal and Gastric Varices Bleeding. Journal of Kunming Medical University, 2022, 43(3): 128-134. doi: 10.12259/j.issn.2095-610X.S20220316
[4]	Qingqing WANG, Jie DING, Hongjie YANG, Guoji CHANG, Siqi LIU, Lijuan HUA, Yiying WANG, Shenghao LI. Predictive Value of RDW and Blood Lipid on Gastroesophageal Variceal Bleeding in Patients with Liver Cirrhosis. Journal of Kunming Medical University, 2022, 43(5): 144-148. doi: 10.12259/j.issn.2095-610X.S20220509
[5]	Min ZHOU, Zhihui MA, Jiayan LI, Jianhua FAN, Ling LIN, Tingying YU, Huifang ZHANG, Li LIU. Predictive Model of Risk Factors for the Recurrence of Liver Cirrhosis with Pleural Effusion. Journal of Kunming Medical University, 2022, 43(5): 149-154. doi: 10.12259/j.issn.2095-610X.S20220524
[6]	Di HE, Peng CHEN, Feng LIU, Yang XU, Lei HAN, Wenjing DING. Progress in Etiology and Pathogenesis of Liver Fibrosis. Journal of Kunming Medical University, 2022, 43(11): 165-171. doi: 10.12259/j.issn.2095-610X.S20221122
[7]	Qin XIE, Yan-ping LIANG, Yin ZHANG, Zeng-hui XU, Li-ying YOU. Efficacy of Multiple Non-invasive Diagnostic Models in the Diagnosis of Hepatic Fibrosis in Patients with Chronic Liver Diseases. Journal of Kunming Medical University, 2021, 42(7): 115-120. doi: 10.12259/j.issn.2095-610X.S20210719
[8]	Jiang Ming Yuan , Huang Hua , Lu Ming Liang , Ding Wen Jing , Wang Jia Ping , Zheng Su Yun , Shi Xin . . Journal of Kunming Medical University, 2020, 41(02): 32-36.
[9]	Sun Yue , Wei Jia , Lu Yong Ping , Wang Jin , Zou Yu , Wang Yu Xue , Yang Mi . Quantitative Analysis on Staging of Chronic Viral Hepatitis B and Hepatic Fibrosis by Real-time Shear Wave Elastography. Journal of Kunming Medical University, 2016, 37(11): 55-59.
[10]	He Min . . Journal of Kunming Medical University,
[11]	Kang Du Fu . . Journal of Kunming Medical University,
[12]	Ji Hong . . Journal of Kunming Medical University,
[13]	Zhang Ying Ying . . Journal of Kunming Medical University,
[14]	Li Ming Ming . . Journal of Kunming Medical University,
[15]	Yang Yong Rui . . Journal of Kunming Medical University,
[16]	Li Wei Hua . . Journal of Kunming Medical University,
[17]	Zeng Jin . . Journal of Kunming Medical University,
[18]	Wang Yun . . Journal of Kunming Medical University,
[19]	. The Treatment of Liver Cirrhosis Complicated with Portal Hypertension by Transjugalar Intrahepatic Portosystemic Shunt (a Follow-up Study of 126 Cases). Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,